Last week, the Internal Revenue Service released the Strategic Operating Plan, which broadly lays out the agency's plans to use $80 billion in funding from the Inflation Reduction Act to transform the ...
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results